在调节器治疗之前和之后,在囊性纤维化患者中使用药物
Louise Lord1, Mark Hew2, Miriam Ty Leung1
1Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Melbourne, Victoria, 3052, Australia.
Pulmonary pharmacology & therapeutics
|November 4, 2024
概括
囊性纤维化外膜导电调节器 (CFTR) 调节器治疗在患有CF的人 (PwCF) 导致减少阿片类药物和精神药物的使用. 药物发行量在五年内稳定,这表明健康结果有所改善.
科学领域:
- 药理学 药理学是指药理学的学科.
- 医学科学 医学科学 医学科学
- 公共卫生 公共卫生
背景情况:
- 长期药物分发模式 囊性纤维化后的跨膜导电调节器 (CFTR) 调节器启动没有得到充分记录.
- 了解这些变化对于评估CFTR调节器对囊性纤维化患者 (PwCF) 的综合影响至关重要.
研究的目的:
- 在开始CFTR调节器治疗后,调查PwCF中药物使用的长期变化.
- 为了比较调节器上的PwCF和匹配的对照组之间的药物发行趋势.
主要方法:
- 利用了2013-2022年澳大利亚制药福利计划 (PBS) 数据的10%样本.
- 采用线性回归来分析PwCF中药物分发,这些药物分发者启动了调节器与匹配的对照.
- 检查了药物开始前和后每月发放的差异,并根据药物类别进行了具体分析.
主要成果:
- 立即启动后,调节器用户的剂量增加了0.9,在大约5年内正常化到控制水平.
- 在7.5年后,调节器使用者显示,与启动前 (β: -0.00131) 和稳定的精神药物使用相比,阿片类药物开放量减少.
- 在调节器使用者中,女性健康药物发行量增加了 (β:0.00026),而在对照者中则下降了.
结论:
- CFTR调节器启动与PwCF中的阿片类药物和精神药物发放量减少有关.
- 在调节器的PwCF中,观察到女性健康药物使用的增加.
- 这些药物发行变化表明,在各种临床领域,患者的治疗结果可能有所改善.
相关概念视频
Cystic Fibrosis: Management
143
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
143
Antiasthma Drugs: Leukotriene Modifiers
246
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
246
Cystic Fibrosis: Pathogenesis
192
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
192
COPD: Management Using Bronchodilators and Corticosteroids
182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
Drugs for Treatment of Constipation-Predominant IBS
137
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
137
Inhaled Medications
237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237


